CORIUM, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1999-01-01
- Employees
- 251
- Market Cap
- -
- Website
- https://corium.com
A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD
Phase 4
Active, not recruiting
- Conditions
- Attention Deficit/Hyperactivity Disorder
- Interventions
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Corium, Inc.
- Target Recruit Count
- 123
- Registration Number
- NCT05721235
- Locations
- 🇺🇸
Advanced Research Center (ARC), Anaheim, California, United States
🇺🇸iResearch Atlanta, Decatur, Georgia, United States
🇺🇸CenExel iResearch, LLC, Savannah, Georgia, United States
An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHD
Phase 4
Completed
- Conditions
- Attention Deficit/Hyperactivity Disorder
- Interventions
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Corium, Inc.
- Target Recruit Count
- 246
- Registration Number
- NCT05685732
- Locations
- 🇺🇸
Advanced Research Center (ARC), Anaheim, California, United States
🇺🇸Sky Clinical Research Network Group P.C., Atlanta, Georgia, United States
🇺🇸CenExel IResearch, LLC - Decatur, Decatur, Georgia, United States
Crossover Pharmacokinetic (PK) Study of 5 and 10 mg Corplex™ Donepezil TDS Compared to 10 mg Aricept® in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- Combination Product: Donepezil TDS
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2021-05-21
- Lead Sponsor
- Corium, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT04617782
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States
A Study to Evaluate the Effect of Heat Application on the Delivery Profile of Corplexâ„¢ Donepezil Transdermal Delivery System (TDS)
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- Corium, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT03438604
- Locations
- 🇺🇸
Celerion, Phoenix, Arizona, United States
A Clinical Study to Evaluate the Pharmacokinetics (PK) of Corplexâ„¢ Donepezil Transdermal Delivery System (TDS) Applied to Different Body Locations
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- Corium, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT03432195
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Skin Irritation Assessment of Once-Weekly Corplexâ„¢ Donepezil Transdermal Delivery System
Phase 1
Completed
- Conditions
- Skin IrritationSensitization
- Interventions
- Drug: Vehicle TDS
- First Posted Date
- 2018-01-12
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- Corium, Inc.
- Target Recruit Count
- 256
- Registration Number
- NCT03397862
- Locations
- 🇺🇸
Celerion Inc., Lincoln, Nebraska, United States
A Bioequivalence Study of Corplex™ Donepezil Transdermal Delivery System Compared to Aricept®
- First Posted Date
- 2017-08-24
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- Corium, Inc.
- Target Recruit Count
- 86
- Registration Number
- NCT03259958
- Locations
- 🇺🇸
Celerion Inc., Phoenix, Arizona, United States
A Phase 1, Corplex™ Donepezil Transdermal System Compared to Oral Aricept®
Phase 1
Completed
- Conditions
- Alzheimer Disease
- Interventions
- First Posted Date
- 2016-11-21
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- Corium, Inc.
- Target Recruit Count
- 107
- Registration Number
- NCT02968719
- Locations
- 🇺🇸
Celerion, Phoenix, Arizona, United States
© Copyright 2025. All Rights Reserved by MedPath